Find clinical trials for Kidney Disease in New Haven, CT
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Kidney Disease trials near New Haven, CT, USA:
A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and a...
Phase 1, Phase 2
New Haven, Connecticut, United States and 8 other locations
To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...
Phase 1
New Haven, Connecticut, United States and 27 other locations
to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...
Phase 3
Hamden, Connecticut, United States and 338 other locations
Primary Objective:Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).Secondary Objectives:* E...
Phase 3
New Haven, Connecticut, United States and 29 other locations
compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...
Phase 2
Waterbury, Connecticut, United States and 116 other locations
CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney...
Phase 2
Stamford, Connecticut, United States and 41 other locations
Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...
Phase 3
New Haven, Connecticut, United States and 337 other locations
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys...
Phase 2
New Haven, Connecticut, United States and 167 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
New Haven, Connecticut, United States and 290 other locations
receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.Empagliflozin lowers blood...
Phase 2
Waterbury, Massachusetts, United States of America and 188 other locations
Clinical trials
Research sites
Resources
Legal